{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T01:37:48Z","timestamp":1787189868845,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ceftolozane\/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and \u03b2-lactamase inhibitor, is approved for the treatment of hospital-acquired\/ventilator-associated bacterial pneumonia (HABP\/VABP) in adults. Participants in the ASPECT-NP trial received ceftolozane\/tazobactam (3\u00a0g [2\u00a0g ceftolozane\/1\u00a0g tazobactam] every 8\u00a0h) or meropenem (1\u00a0g every 8\u00a0h). Participants failing prior antibacterial therapy for the current HABP\/VABP episode at study entry had lower 28-day all-cause mortality (ACM) rates with ceftolozane\/tazobactam versus meropenem treatment. Here, we report a post hoc analysis examining this result.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The phase 3, randomized, controlled, double-blind, multicenter, noninferiority trial compared ceftolozane\/tazobactam versus meropenem for treatment of adults with ventilated HABP\/VABP; eligibility included those failing prior antibacterial therapy for the current HABP\/VABP episode at study entry. The primary and key secondary endpoints were 28-day ACM and clinical response at test of cure (TOC), respectively. Participants who were failing prior therapy were a prospectively defined subgroup; however, subgroup analyses were not designed for noninferiority testing. The 95% CIs for treatment differences were calculated as unstratified Newcombe CIs. Post hoc analyses were performed using multivariable logistic regression analysis to determine the impact of baseline characteristics and treatment on clinical outcomes in the subgroup who were failing prior antibacterial therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the ASPECT-NP trial, 12.8% of participants (93\/726; ceftolozane\/tazobactam,<jats:italic>n<\/jats:italic>\u2009=\u200953; meropenem,<jats:italic>n<\/jats:italic>\u2009=\u200940) were failing prior antibacterial therapy at study entry. In this subgroup, 28-day ACM was higher in participants who received meropenem versus ceftolozane\/tazobactam (18\/40 [45.0%] vs 12\/53 [22.6%]; percentage difference [95% CI]: 22.4% [3.1 to 40.1]). Rates of clinical response at TOC were 26\/53 [49.1%] for ceftolozane\/tazobactam versus 15\/40 [37.5%] for meropenem (percentage difference [95% CI]: 11.6% [\u2212\u20098.6 to 30.2]). Multivariable regression analysis determined concomitant vasopressor use and treatment with meropenem were significant factors associated with risk of 28-day ACM. Adjusting for vasopressor use, the risk of dying after treatment with ceftolozane\/tazobactam was approximately one-fourth the risk of dying after treatment with meropenem.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This post hoc analysis further supports the previously demonstrated lower ACM rate for ceftolozane\/tazobactam versus meropenem among participants who were failing prior therapy, despite the lack of significant differences in clinical cure rates.<\/jats:p><jats:p><jats:italic>ClinicalTrials.gov registration<\/jats:italic><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02070757\">NCT02070757<\/jats:ext-link>. Registered February 25, 2014,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02070757\">clinicaltrials.gov\/ct2\/show\/NCT02070757<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13054-022-04192-w","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:16:00Z","timestamp":1669918560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired\/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane\/tazobactam versus meropenem"],"prefix":"10.1186","volume":"26","author":[{"given":"Marin H.","family":"Kollef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Wunderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin H.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"5","key":"4192_CR1","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"4192_CR2","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198\u2013208.","journal-title":"N Engl J Med"},{"issue":"19","key":"4192_CR3","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMra0904124","volume":"362","author":"AY Peleg","year":"2010","unstructured":"Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804\u201313.","journal-title":"N Engl J Med"},{"issue":"3","key":"4192_CR4","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J. 2017;50(3):1700582.","journal-title":"Eur Respir J"},{"issue":"157","key":"4192_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0023-2020","volume":"29","author":"MS Vallecoccia","year":"2020","unstructured":"Vallecoccia MS, Dominedo C, Cutuli SL, Martin-Loeches I, Torres A, De Pascale G. Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia? Eur Respir Rev. 2020;29(157): 200023.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"4192_CR6","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1093\/cid\/ciaa1712","volume":"73","author":"SM Bart","year":"2021","unstructured":"Bart SM, Rubin D, Kim P, Farley JJ, Nambiar S. Trends in hospital-acquired and ventilator-associated bacterial pneumonia trials. Clin Infect Dis. 2021;73(3):e602\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4192_CR7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","volume":"50","author":"MD Zilberberg","year":"2021","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012\u20132019. Crit Care Med. 2021;50(3):460\u20138.","journal-title":"Crit Care Med"},{"issue":"6","key":"4192_CR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","volume":"18","author":"MD Zilberberg","year":"2014","unstructured":"Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596.","journal-title":"Crit Care"},{"issue":"12","key":"4192_CR9","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/cid\/ciz1187","volume":"71","author":"OR Albin","year":"2020","unstructured":"Albin OR, Henig O, Patel TS, Valley TS, Pogue JM, Petty LA, et al. Clinical implications of microbiologic treatment failure in the setting of clinical cure of bacterial pneumonia. Clin Infect Dis. 2020;71(12):3033\u201341.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4192_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjms.2018.11.009","volume":"357","author":"NG Bonine","year":"2019","unstructured":"Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, et al. Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious gram-negative bacterial infections. Am J Med Sci. 2019;357(2):103\u201310.","journal-title":"Am J Med Sci"},{"key":"4192_CR11","doi-asserted-by":"crossref","unstructured":"Klinker K, DePestel D, Motyl M, DeRyke C, editors. Frequency of carbapenem-resistant Pseudomonas aeruginosa among respiratory pathogens impacts first-line beta-lactam susceptibility: potential role for ceftolozane\/tazobactam and\/or imipenem\/relebactam. In: IDWeek; 2020; Virtual Meeting.","DOI":"10.1093\/ofid\/ofaa439.1631"},{"issue":"7","key":"4192_CR12","doi-asserted-by":"publisher","first-page":"ofab320","DOI":"10.1093\/ofid\/ofab320","volume":"8","author":"SH Lob","year":"2021","unstructured":"Lob SH, DePestel DD, DeRyke CA, Kazmierczak KM, Young K, Motyl MR, et al. Ceftolozane\/tazobactam and imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards-SMART United States 2017\u20132019. Open Forum Infect Dis. 2021;8(7):ofab320.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"4192_CR13","doi-asserted-by":"publisher","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","volume":"5","author":"E McCann","year":"2018","unstructured":"McCann E, Srinivasan A, DeRyke CA, Ye G, DePestel DD, Murray J, et al. Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5(10):ofy241.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"4192_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","volume":"43","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009\u20132012. Int J Antimicrob Agents. 2014;43(4):328\u201334.","journal-title":"Int J Antimicrob Agents"},{"key":"4192_CR15","volume-title":"Global action plan on antimicrobial resistance","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO Press; 2018."},{"issue":"10","key":"4192_CR16","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","volume":"43","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43(10):1464\u201375.","journal-title":"Intensive Care Med"},{"issue":"7","key":"4192_CR17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/resp.13115","volume":"22","author":"A Rodrigo-Troyano","year":"2017","unstructured":"Rodrigo-Troyano A, Sibila O. The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirology. 2017;22(7):1288\u201399.","journal-title":"Respirology"},{"issue":"1","key":"4192_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","volume":"74","author":"GG Zhanel","year":"2014","unstructured":"Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31\u201351.","journal-title":"Drugs"},{"key":"4192_CR19","doi-asserted-by":"publisher","first-page":"e02125","DOI":"10.1128\/AAC.02125-17","volume":"62","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. Antimicrob Agents Chemother. 2018;62:e02125-e2217.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4192_CR20","doi-asserted-by":"publisher","first-page":"114925","DOI":"10.1016\/j.diagmicrobio.2019.114925","volume":"96","author":"JA Karlowsky","year":"2020","unstructured":"Karlowsky JA, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum beta-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis. 2020;96(4):114925.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"4192_CR21","doi-asserted-by":"publisher","first-page":"105883","DOI":"10.1016\/j.ijantimicag.2020.105883","volume":"55","author":"SC Kuo","year":"2020","unstructured":"Kuo SC, Liu CE, Lu PL, Chen YS, Lu MC, Ko WC, et al. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015\u20132016. Int J Antimicrob Agents. 2020;55(3):105883.","journal-title":"Int J Antimicrob Agents"},{"key":"4192_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jgar.2019.10.009","volume":"21","author":"D Shortridge","year":"2020","unstructured":"Shortridge D, Pfaller MA, Streit JM, Flamm RK. Antimicrobial activity of ceftolozane\/tazobactam tested against contemporary (2015\u20132017) Pseudomonas aeruginosa isolates from a global surveillance programme. J Glob Antimicrob Resist. 2020;21:60\u20134.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4192_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12866-021-02135-z","volume":"21","author":"JA Karlowsky","year":"2021","unstructured":"Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections\u2014SMART United States 2018\u20132019. BMC Microbiol. 2021;21(1):74.","journal-title":"BMC Microbiol"},{"issue":"12","key":"4192_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, R\u00e9a-Neto \u00c1, Shime N, Martin-Loeches I, et al. Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299\u2013311.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4192_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jinf.2018.04.002","volume":"77","author":"K Ryan","year":"2018","unstructured":"Ryan K, Karve S, Peeters P, Baelen E, Potter D, Rojas-Farreras S, et al. The impact of initial antibiotic treatment failure: Real-world insights in healthcare-associated or nosocomial pneumonia. J Infect. 2018;77(1):9\u201317.","journal-title":"J Infect"},{"key":"4192_CR26","unstructured":"ZERBAXA [prescribing information]. Whitehouse Station (NJ): Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.; 2019."},{"key":"4192_CR27","unstructured":"M100\u2011ED30: 2020 Performance Standards for Antimicrobial Susceptibility Testing [Internet]. Clinical Laboratory Standards Institute. 2020. Available from: https:\/\/clsi.org\/standards\/products\/free\u2011resources\/access\u2011our\u2011free\u2011resources\/."},{"issue":"3","key":"4192_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1198\/sbr.2009.0049","volume":"2","author":"X Yan","year":"2010","unstructured":"Yan X, Su XG. Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions. Stat Biopharm Res. 2010;2(3):329\u201335.","journal-title":"Stat Biopharm Res"},{"issue":"1","key":"4192_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13054-021-03694-3","volume":"25","author":"JF Timsit","year":"2021","unstructured":"Timsit JF, Huntington JA, Wunderink RG, Shime N, Kollef MH, Kivistik U, et al. Ceftolozane\/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Crit Care. 2021;25(1):290.","journal-title":"Crit Care"},{"key":"4192_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45:5\u201332.","journal-title":"Mach Learn"},{"issue":"3","key":"4192_CR31","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(3):18\u201322.","journal-title":"R News"},{"issue":"1","key":"4192_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00134-017-4962-2","volume":"44","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Montero JG, Paiva JA. When antibiotic treatment fails. Intensive Care Med. 2018;44(1):73\u20135.","journal-title":"Intensive Care Med"},{"issue":"11","key":"4192_CR33","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/cid\/ciz093","volume":"69","author":"E Weiss","year":"2019","unstructured":"Weiss E, Zahar J-R, Alder J, Asehnoune K, Bassetti M, Bonten MJ, et al. Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired\/ventilator-associated bacterial pneumonia clinical trials. Clin Infect Dis. 2019;69(11):1912\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4192_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13613-019-0498-7","volume":"9","author":"TWL Scheeren","year":"2019","unstructured":"Scheeren TWL, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC, et al. Current use of vasopressors in septic shock. Ann Intensive Care. 2019;9(1):20.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4192_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jac\/dku354","volume":"70","author":"F Frippiat","year":"2015","unstructured":"Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015;70(1):207\u201316.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4192_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13054-020-02883-w","volume":"24","author":"F Frippiat","year":"2020","unstructured":"Frippiat F, Vercheval C, Layios N. Meropenem: continuous or extended infusion? Crit Care. 2020;24(1):192.","journal-title":"Crit Care"},{"issue":"1","key":"4192_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s13054-021-03773-5","volume":"25","author":"AF Shorr","year":"2021","unstructured":"Shorr AF, Bruno CJ, Zhang Z, Jensen E, Gao W, Feng HP, et al. Ceftolozane\/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Crit Care. 2021;25(1):354.","journal-title":"Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04192-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T08:46:17Z","timestamp":1701506777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04192-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4192"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04192-w","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. All participants, or their legal representatives, had to provide written informed consent in order to be eligible for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MHK is a consultant for MSD and Shionogi and his efforts are supported by the Barnes-Jewish Hospital Foundation. JFT has received institutional research support from MSD. IML has received institutional research support from MSD. RGW has received institutional research support and consultancy fees from MSD. JAH, EHJ, BY, and CJB are employees of MSD, and own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}